Chemo-radiotherapy and autologous bone marrow transplantation in poor prognosis neuroblastoma

Radiother Oncol. 1990:18 Suppl 1:102-4. doi: 10.1016/0167-8140(90)90185-y.

Abstract

In Genoa, 39 patients affected by disseminated neuroblastoma, one to twelve years old, were treated with intensive chemotherapy (Vincristine 4 mg/sqm c.i. over 5 days, Melphalan 140 mg/sqm), total body irradiation (TBI) (3.3 Gy for 3 days), and unpurged autologous bone marrow transplantation (ABMT) since October 1984 until November 1987. Thirty-two patients were in complete response (first group) and 7 had residual disease (second group) after an intensive chemotherapeutic induction regimen. Actuarial overall survival at 38 months is 52% and disease free survival at 30 months is 28% for the first group. Actuarial overall survival at 25 months is instead 14% for the second group related treatment toxicity has not been too high (3 deaths).

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Marrow Transplantation / methods*
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Female
  • Humans
  • Infant
  • Male
  • Neoplasm Staging
  • Nervous System Neoplasms / mortality
  • Nervous System Neoplasms / pathology
  • Nervous System Neoplasms / surgery
  • Nervous System Neoplasms / therapy*
  • Neuroblastoma / mortality
  • Neuroblastoma / pathology
  • Neuroblastoma / surgery
  • Neuroblastoma / therapy*
  • Survival Rate
  • Transplantation, Autologous
  • Whole-Body Irradiation*